Skip to main content
. Author manuscript; available in PMC: 2019 Jan 22.
Published in final edited form as: Cell Rep. 2018 Dec 4;25(10):2808–2820.e4. doi: 10.1016/j.celrep.2018.11.035

Figure 6. Simultaneous EZH2 and AR Targeting Remarkably Inhibited PCa Cell Growth.

Figure 6.

(A) Combinatorial GSK126 and enzalutamide (Enz) treatment significantly inhibited LNCaP cell growth and drug resistance. LNCaP cells were maintained in DMSO, GSK126 (0.5uM), Enz (0.5uM), or both for 55 days. Cells were counted and re-plated whenever needed, and accumulated cell numbers were determined. Data shown are for one representative experiment of two.

(B and C) LNCaP (B) or C4–2B (C) cells were treated with DMSO, Enz (1 μM for LNCaP and10 μM for C4–2B), EPZ (1 μM), or both. Cell growth was measured with WST-1 reagent every 2 days. Data shown are mean ± SEM of technical replicates from one representative experiment of three.

(D and E) LNCaP (D) or C4–2B (E) cells were treated with DMSO, Enz (1 μM for LNCaP and 10 μM for C4–2B), EPZ (1 μM), or both for 2 weeks, followed by 0.002% crystal violet staining to assay colony formation. Data shown are technical replicates from one representative experiment of three.

(F and G) Combinatorial Enz and EPZ treatment induced cell cycle arrest. LNCaP (F) or C4–2B (G) cells were treated with DMSO, Enz (1 μM for LNCaP and 10 μM for C4–2B), EPZ (1 μM), or both for 3 days, followed by cell cycle analysis via flow cytometry with propidium iodide staining.